Cytogenetic toxicity of cycloplatam in human lymphocytes: Detection by the micronucleus test and fluorescence in situ hybridization

Anti-Cancer Drugs

Volumn 17, Issue 3, 2006, Pages 289-295

  Nersesyan, Armen ^a   Perrone, Emanuela ^b   Roggieri, Paola ^b   Bolognesi, Claudia ^b  

^a Cancer Research Institute   (Armenia)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Aneugenic effects; Carboplatin; Cisplatin; Clastogenic damage; Cycloplatam; Cytogenetic effects; Fluorescence in situ hybridization; Genotoxicity; Micronucleus test; Platinum drugs

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPLATAM; DNA; MITOMYCIN C; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CENTROMERE; CHROMOSOME; CONTROLLED STUDY; CYTOGENETICS; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MICRONUCLEUS TEST; PRIORITY JOURNAL;

CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; ORGANOPLATINUM COMPOUNDS;

EID: 33646099381     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200603000-00007     Document Type: Article

References (42)

1. Presnov MA, Konovalova AL. Cycloplatam and oxoplatin - the new antitumor platinum compounds of the second generation. Arch Geschwulstforsch 1980; 1:43-49.
2. Bagrova SG. Results of phase II clinical trial of cycloplatam in refractory solid tumors. Vopr Oncol 2001; 47:752-756.
3. Gorbunova VA. Cycloplatam: The results of clinical trials of solid tumors. Moscow, Russia: Moscow Society of Oncologists; 2004. Report No. N11, 5-12.
4. Gorbunova VA. Chemotherapy of ovary cancer. Russian Med J 2001; 9:974-978.
5. Topchieva CV, Orel NF, Gorbunova VA. Clinical study of cycloplatam in patients with disseminated ovary cancer. In: Proceedings of the VI Russian National Congress 'Man and Drug', Moscow; 1999. p. 245.
6. Bakhteeva VT, Fok EM, Lavrova EA. Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects. Vopr Med Khim 1996; 42:301-306.
7. Natochin IV, Beznik LV, Brovtsin VK, Ivanov VB, Miazina EM, Chel'tsov PA, et al. Characteristics of the action of cisplatin and cycloplatam on the rat kidney. Bull Eksp Biol Med 1989; 108:52-54.
8. Drees M, Dengler WM, Hendriks HR, Kelland LR, Fiebig HH. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Eur J Cancer 1995; 31A:356-361.
9. Konovalova AL, Cheltsov PA, Stetsenko AI, Syrkin AB. Antitumor activity of new platinum complexes. In: Proceedings of the 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam; 1992. pp. 92-93.
10. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2:275-280.
11. Siemer S, Ornskov D, Guerra B, Boldyreff B, Issinger OG. Determination of mRNA, and protein levels p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin. Int J Biochem Cell Biol 1999; 31:661-670.
12. Sokolovskaya AA, Zabotina TN, Blokhin DY, Inshakov AN, Mikhailov AD, Kadagidze ZG, et al. Comparative analysis of apoptosis induced by various advanced drugs in Jurkat cells. Exp Oncol 2001; 23:48-50.
13. Perrin LC, Cullinane C, McFadyen WD, Phillips DR. Sequence specificity and reactivity of the binding of platinum complexes to DNA. Anticancer Drug Des 1999; 14:243-252.
14. Butour JL, Wimmer S, Wimmer F, Castan P. Palladium (II) compounds with potential antitumour properties and their platinum analogues: a comparative study of the reaction of some orotic acid derivatives with DNA in vitro. Chem Biol Interact 1997; 104:165-178.
15. Bose RN. Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2002; 2:103-111.
16. Garriott ML, Phelps JB, Hoffman WP. A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. Mutat Res 2002; 517:123-134.
17. Miller B, Potter-Locher F, Seelbach A, Stopper H, Utesch D, Madle S. Evaluation of the in vitro micronucleus test as an alternative to the in vitro chromosomal aberration assay: position of the GUM working group on the in vitro micronucleus test. Mutat Res 1988; 410:81-116.
18. Heddle JA, Carrano AV. The DNA content of micronuclei in mouse bone marrow by gamma radiation: evidence that micronuclei arise from acentric fragments. Mutat Res 1977; 49:63-69.
19. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985; 147:29-36.
20. Fenech M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res 1993; 285:35-44.
21. Nersesyan A, Perrine E, Roggieri P, Bolognesi C. Genotoxic action of Cycloplatam a new platinum antitumor drug, on mammalian cells in vivo and in vitro. Chemotherapy 2003; 49:132-137.
22. Fenech M, Crott J, Turner J, Brown S. Necrosis, apoptosis, cytostasis and DNA damage in human lymphocytes measured simultaneously within the cytokinesis-block micronucleus assay: description of the method and results for hydrogen peroxide. Mutagenesis 1999; 14:605-612.
23. Kimura M, Umegaki K, Higuchi M, Thomas P, Fenech M. Methylenetetrahydrofolate reductase C677T polymorphism, folic acid and riboflavin are important determinants of genome instability in cultured human lymphocytes. J Nutr 2004; 134:48-56.
24. Eastmond DA, Schuler M, Rupa DS. Advantage and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Mutat Res 1995; 348:153-162.
25. Zijno A, Leopardi P, Marcon F, Crebelli R. Analysis of chromosome segregation by means of fluorescence in situ hybridization: application to cytokinesis-blocked human lymphocytes. Muta Res 1996; 372: 211-219.
26. Tucker JD, Eastmond DA, Littlefield LG. Cytogenetic endpoints as biological dosimeters and predictors of risk in epidemiological studies. In: Toniolo P, Boffetta P, Shaker DEG, Rothman N, Hulka B, Pearce N (editors): Application of Biomarkers In Cancer Epidemiology (IARC Scientific Publication 142). Lyon: IARC; 1997. pp.185-200.
27. Miller BM, Adler ID. Application of antikineticore antibody staining (CREST staining) to micronuclei in erythrocytes induced in vivo. Mutagenesis 1990; 5:411-415.
28. Surralles J, Catalan J, Creus A, Norppa H, Xamena N, Marcos R. Micronuclei induced by alachlor, mitomycin-C and vinblastine in human lymphocytes: presence of centromeres and kinetochores and influence of staining technique. Mutagenesis 1995; 10:417-423.
29. Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res 1996; 355:59-70.
30. Rodilla V. Origin and evolution of binucleated cells and binucleated cells with micronuclei in cisplatin-treated CHO cultures. Mutat Res 1993; 300:281-291.
31. Rodilla V, Pellicer JA, Serrano A, Pertusa J. Possible relationship between micronucleated and binucleated cells induced by cisplatin in cultured CHO cells. Mutat Res 1993; 291:35-41.
32. Tominaga K, Shinkai T, Saijo N, Eguchi K, Shimizu E, Sasaki Y, et al. Sister chromatid exchanges induced in human lymphocytes by cis-diamminedichloro platinum (II). Jpn J Clin Oncol 1984; 14:659-665.
33. Choudhury RC, Jagdale MB, Misra S. Cytogenetic toxicity of cisplatin in bone marrow cells of Swiss mice. J Chemother 2000; 12:173-182.
34. Tandon P, Sodhi A. Cis-dichlorodiammine platinum (II) induced aberrations in mouse bone marrow chromosomes. Mutat Res 1985; 156:187-193.
35. Edelwiss MI, Trachtenberg A, Pinheiro EX, da Silva J, Riegel M, Lizardo-Daud HM. Clastogenic effect of cisplatin on Wistar rat bone marrow cells. Braz J Med Biol Res 1995; 28:679-683.
36. Elsendoorn TJ, Weijl NJ. Chemotherapy induced chromosomal damage in peripheral blood lymphocyte and cancer patients supplemented with antioxidants or placebo. Mutat Res 2001; 498:145-158.
37. De Mas P, Daudin M, Vincent M, et al. Increased aneuploidy in spermatozoa from testicular tumour patients after chemotherapy with cisplatin, etoposide and bleomycin. Hum Reprod 2001; 16:1204-1208.
38. Overbeck TL, Knight JM, Beck DJ. A comparison of the genotoxic effects of carboplatin and cisplatin in Escherichia coli. Mutat Res 1996; 362:249-259.
39. Shinkai T, Saijo N, Eguchi K. Cytogenetic effect of carboplatin on human lymphocytes. Cancer Chemother Pharmacol 1988; 21:203-207.
40. Quintana E, Pertusa J, Gonzales R, Renau-Piqueras J. Carboplatin treatment induces dose-dependent increases in the frequency of micronuclei in Erlich ascites tumor cells. Mutat Res 1994; 322:55-60.
41. Blommaert FA, van Dijk-Knijnenburg HCM, Dijt FJ, Den Engelse L, Baan RA, Berends F, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 1995; 34:8474-8480.
42. Terheggen PMAB, Beg AC, Edmond JY, Dubbelman R, Floot BGJ, Den Engelse L. Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. Br J Cancer 1991; 63:195-200.